Long-term analysis of the palliative benefit of 2-Chlorodeoxyadenosine (2-CdA) for myelofibrosis with myeloid metaplasia.

@article{Faoro2004LongtermAO,
  title={Long-term analysis of the palliative benefit of 2-Chlorodeoxyadenosine (2-CdA) for myelofibrosis with myeloid metaplasia.},
  author={Leonardo Nercolini Faoro and Reyes L{\'o}pez de Mesa and Morie A Gertz and Ayalew Tefferi},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2004},
  volume={22 14_suppl},
  pages={6620}
}
6620 Background:Therapeutic splenectomy in myelofibrosis with myeloid metaplasia (MMM) may result in extreme thrombocytosis and leukocytosis as well as accelerated hepatomegaly. We have previously reported on our short-term treatment experience with the purine nucleoside analog 2-chlorodeoxyadenosine (2-CdA) in such instances (Brit J Haem 1997;99(2):352.). We have since treated more patients with 2-CdA and provide information on the long-term treatment experience. METHODS 2-CdA was… CONTINUE READING
BETA